Biodesix, Inc.
2970 Wilderness Place
Suite 100
Boulder
Colorado
80301
United States
Tel: 303-417-0500
Website: http://www.biodesix.com/
Email: info@biodesix.com
205 articles about Biodesix, Inc.
-
Biodesix Announces Closing of New $30 Million Term Loan
3/23/2021
Biodesix, Inc. a leading data-driven diagnostic solutions company with a focus in lung disease, announced that it has closed on a new $30 million term loan which matures on March 1, 2026.
-
Biodesix to Report Fourth Quarter and Fiscal 2020 Financial Results on March 16, 2021
3/9/2021
Biodesix, Inc., a leading data-driven diagnostic solutions company with a focus in lung disease, announced that it will release financial results for the fourth quarter and year ended December 31, 2020 after the close of trading on Tuesday, March 16.
-
Biodesix CEO Scott Hutton Selected as One of Top 25 Biotech CEOs of 2021
2/25/2021
Biodesix, Inc., a leading data-driven diagnostic solutions company with a focus in lung disease, announced that The Healthcare Technology Report announced Chief Executive Officer, Scott Hutton, as one of the Top 25 Biotech CEOs of 2021.
-
Biodesix Partners with Chicago Public Schools for COVID-19 Testing to Safely Reopen Schools
2/16/2021
Biodesix, Inc., a leading data-driven diagnostic solutions company with a focus in lung disease, announced that the company has partnered with Chicago Public Schools to provide antigen and Droplet Digital PCR ™ testing for Chicago Public School teachers and staff.
-
Biodesix to Participate in Two February Conferences
2/12/2021
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that management will participate in two upcoming conferences: the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which is being held February 17-19, 2021, and the LifeSci Partners Precision Oncology Day, which is being held February 17, 2021.
-
Biodesix Publishes Data on New COVID-19 Artificial Intelligence (AI)-Based Algorithm for Use in Clinical Decision Support Systems
2/9/2021
New Data Show AI-Based Algorithm Rapidly Predicts Risk of Severe Outcomes for Patients Hospitalized for COVID-19 Infection
-
Scott Hutton of Biodesix Selected as USA Chief Executive Officer of the Year by CEO Monthly Magazine
2/2/2021
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that Chief Executive Officer Scott Hutton was selected as the CEO of the Year, 2020
-
Biodesix to Showcase New Data on Patient Immune Profiling from Multiple Studies at World Lung Conference
1/26/2021
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that three abstracts from multiple clinical studies will be featured at the International Association for the Study of Lung Cancer (IASLC)
-
Biodesix Anticipates Strong Preliminary Fourth Quarter 2020 Revenue (unaudited)
1/8/2021
Record quarterly revenue driven by strength in COVID-19 testing and growth in lung diagnostic testing
-
Biodesix Announces Hiring of Ryan Siurek as Chief Accounting Officer
1/5/2021
Biodesix, Inc., a leading data-driven diagnostic solutions company with a focus in lung disease, announced that Ryan Siurek has joined the company as Chief Accounting Officer reporting to Ms. Robin Harper Cowie, Chief Financial Officer.
-
Biodesix Initiates Biomarker Study to Affirm Nodify XL2® Test’s Importance in Clinical Decision Making
12/23/2020
Dr. Gerard A. Silvestri of Medical University of South Carolina Named Principal Investigator
-
Biodesix Study Shows Proprietary Device Collects, Separates, and Transports Blood at Ambient Temperature
12/15/2020
Findings Suggest Blood Collection Device Simplifies Specimen Collection and Transport While Maintaining Accuracy of Diagnostic Test Results
-
Biodesix Announced Third Quarter 2020 Results and Provides Corporate Update
12/10/2020
Generates record quarterly revenue of $9.2 million Raises net proceeds of $63 million through initial public offering Adds to the significant and growing body of evidence demonstrating the clinical value of its portfolio of blood based diagnostic tests for lung disease
-
Biodesix Publishes Extended Analyses of the Nodify XL2® Lung Nodule Test
12/1/2020
Biodesix, Inc. a leading data-driven diagnostic solutions company with a focus in lung disease, announced publication of an analysis of the company’s Nodify XL2® lung nodule test.
-
Biodesix Announces Closing of Initial Public Offering
10/30/2020
Biodesix, Inc. (Nasdaq: BDSX) (“Biodesix”) today announced the closing of its initial public offering of 4,000,000 shares of its common stock at a public offering price of $18.00 per share.
-
Biodesix Announces Pricing of Initial Public Offering - Oct 28, 2020
10/28/2020
Biodesix, Inc. announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a public offering price of $18.00 per share.
-
Biodesix Announces Data from Three Studies on Lung Nodule Diagnosis and Management to be Shared at CHEST Annual Meeting 2020
10/20/2020
Biodesix, Inc. a leading data-driven diagnostic solutions company with a focus in lung disease, recently published data from three clinical studies, which found important new information on diagnosis and management of lung nodules.
-
Addario Lung Cancer Medical Institute and Biodesix Initiate Prospective Study to Predict Overall Survival Using Checkpoint Immunotherapy for Front-Line Lung Cancer in Patients with High PDL1 Expression
8/31/2020
Addario Lung Cancer Medical Institute (ALCMI) and Biodesix, Inc. today announced they will begin an observational study to prospectively evaluate the clinical utility of biomarkers, including the proteomic Primary Immune Response (PIR) test, for front-line non-small cell lung cancer (NSCLC) patients receiv
-
Biodesix to Provide COVID-19 Testing for Colorado State University Campus
8/12/2020
Biodesix, Inc. , a leading diagnostic company with a focus in lung disease, today announced plans to provide COVID-19 ddPCR diagnostic testing for Colorado State University (CSU) as students return to campus for the fall term, which begins August 24. “The health and safety of our nation’s students, and the faculty and staff that teach, guide, an
-
Biodesix Appoints Jean Franchi and Hany Massarany to Board of Directors
7/20/2020
Biodesix, Inc. a leader in lung cancer diagnostics, announced the appointment of Jean Franchi and Hany Massarany to the company’s board of directors.